SentryX key facts
as of Oct 2026- Operator of a non-opioid therapeutic platform intended for the treatment of acute pain following musculoskeletal surgery.
- SentryX is valued at approximately $38.7M as of Oct 2026 (last reported valuation).
- It has raised $3.8M.
- Notable investors include European Innovation Council, Utrecht Holdings, Utrecht Health Seed Fund.
- Status: Privately Held (backing).
SentryX's last reported valuation, Apr 2021. Nothing priced has surfaced since.
- ·Watch SentryX: the Monday email on marks, rounds and moves
SentryX funding rounds
No funding rounds for SentryX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs SentryX
3SentryX valuation
SentryX's last reported valuation was $38.7 million in Apr 2021. No priced round, secondary trade or fund mark has surfaced since.
SentryX investors
3 investors are on record for SentryX, including European Innovation Council, Utrecht Holdings and Utrecht Health Seed Fund.
About SentryX
Operator of a non-opioid therapeutic platform intended for the treatment of acute pain following musculoskeletal surgery. The company's platform utilizes localized pain management strategies that reduce reliance on systemic opioid-based treatments with advanced drug delivery mechanisms to target affected areas directly, enabling healthcare providers to offer safer and more effective pain relief for patients undergoing orthopedic procedures.
- Sector
- Healthcare
- HQ
- Utrecht, Netherlands
- Founded
- 2017
- Employees
- 21
- Website
- sentryx.nl/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.